However, despite substantial crosstalk between HER2 and ER and PR signaling pathways, the presence of HR expression in patients with HER2+ early-stage breast cancer remains a predictive biomarker for response to ET30,31, and both ERs and HER2 receptors prevail as drivers of tumor growth. Here, ERBB2 is linked to neoplasm.